Prevalence of NAFLD in T1DM Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorZiekenhuis Oost-Limburg
About this trial
To determine the prevalence of NAFLD in T1DM patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
T1DM
≥ 18 years of age
Written informed consent obtained
Disqualifiers
Excessive alcohol use
Exclusion of other causes of liver disease and secondary causes of liver steatosis
Trial design
Design model
Single group
Treatments tested in this trial
FibroScan
Diagnostic testPerformance of a FibroScan measurement to determine steatosis and fibrosis.
Treatment groups
138 Participants
are divided into 1 treatment groupGroup A: Study cohortOther 1 intervention
Trial outcomes
Primary outcomes
1
Prevalence of NAFLD in T1DM
To determine the prevalence of steatosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with controlled attenuation parameter (CAP) measurements.
Time frame
During the intervention2
Prevalence of fibrosis in T1DM
To determine the prevalence of fibrosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with vibration controlled attenuation parameter (VCTE) measurements.
Time frame
During the interventionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov